Search Within

Elisa De Stanchina

Formats
  1. Journal Article (244)
  2. Meeting Abstract (104)
  3. Book Section (4)
  4. Research Letter (3)
  5. Book Whole (1)
  6. Correspondence (1)
  7. Review (1)
Groups
  1. GSK Faculty (288)
  2. Sloan Kettering Institute Postdocs (257)
  3. Department of Medicine (251)
  4. Solid Tumor Oncology Division (206)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (160)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (154)

More Groups

People
  1. Charles Rudin (70)
  2. Marissa Mattar (44)
  3. Marc Ladanyi (43)
  4. Neal Rosen (37)
  5. Inna Khodos (35)
  6. Romel Somwar (33)

More People

Years
  1. 2025 (22)
  2. 2024 (30)
  3. 2023 (23)
  4. 2022 (51)
  5. 2021 (43)
  6. 2020 (28)

More Years

Publications
  1. Cancer Research (52)
  2. Cancer Discovery (25)
  3. Clinical Cancer Research (19)
  4. Blood (16)
  5. Journal of Thoracic Oncology (16)
  6. Journal of Clinical Oncology (15)

More Publications

Publishers
  1. American Association for Cancer Research (112)
  2. Nature Publishing Group (45)
  3. Cell Press (37)
  4. Elsevier Inc. (27)
  5. American Society of Clinical Oncology (18)
  6. American Society of Hematology (16)

More Publishers

Results (358)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Induction of secreted soluble decoy EGFR variants by splicing interference overcomes drug resistance in human non-small cell lung cancer
    Meeting Abstract

    Park, J. E.; Spraggon, L.; de Stanchina, E.; Cartegni, L.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Targeting HDAC3 reactivates immunosurveillance and enhances immunocheckpoint activity in B-cell lymphoma
    Meeting Abstract

    Mondello, P.; Teater, M.; Fontan, L.; Durant, M.; De Stanchina, E.; Inghirami, G.; Green, M.; Melnick, A.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Preclinical evaluation of enhanced irofulven antitumor activity in an ERCC3 mutant background by in vitro and in vivo tumor models
    Meeting Abstract

    Topka, S.; Khalil, S.; De Stanchina, E.; Vijai, J.; Offit, K.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
    Meeting Abstract

    Yao, Z.; Gao, Y.; Su, W.; Yaeger, R.; Na, N.; Zhang, Y.; Zhang, C.; Rymar, A.; Tao, A.; Torres, N.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • PARP inhibitor radiosensitization of small cell lung cancer differs by PARP trapping potency
    Meeting Abstract

    Lok, B.; Laird, J.; Ma, J.; De Stanchina, E.; Poirier, J.; Rudin, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
    Journal Article

    Ruscetti, M.; Leibold, J.; Bott, M. J.; Fennell, M.; Kulick, A.; Salgado, N. R.; Chen, C. C.; Ho, Y. J.; Sanchez-Rivera, F. J.; Feucht, J.; more...
    Science (2018)

    Fulltext@MSK | Save
  • PARP trapping by talazoparib is a potent mechanism of radiosensitization in small cell lung cancer cell lines and patient-derived xenografts
    Meeting Abstract

    Laird, J. H. Jr; Lok, B. H.; Ma, J.; Bell, A.; De Stanchina, E.; Poirier, J.; Rudin, C. M.
    International Journal of Radiation Oncology, Biology, Physics (2018)

    Fulltext@MSK | Save
  • NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
    Journal Article

    Liu, Y.; Mondello, P.; Erazo, T.; Tannan, N. B.; Asgari, Z.; de Stanchina, E.; Nanjangud, G.; Seshan, V. E.; Wang, S.; Wendel, H. G.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save
  • Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts
    Journal Article

    Laird, J. H.; Lok, B. H.; Ma, J.; Bell, A.; de Stanchina, E.; Poirier, J. T.; Rudin, C. M.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save